Open Access

Synaptonemal complex protein 3 is associated with lymphangiogenesis in non-small cell lung cancer patients with lymph node metastasis

Contributed equally
Journal of Translational Medicine201715:138

https://doi.org/10.1186/s12967-017-1241-5

Received: 6 February 2017

Accepted: 9 June 2017

Published: 17 June 2017

Abstract

Background

The interaction of vascular endothelial growth factor-C (VEGF-C)/VEGF-D/VEGF receptor-3 is considered to be a major driver of lymphangiogenesis, however the mechanism of this process remains unclear. We aimed to investigate the possible lymphangiogenic significance of synaptonemal complex protein 3 (SCP3) in non-small cell lung cancer (NSCLC).

Methods

The expression of SCP3, VEGF-C, and VEGF-D were measured and examined a correlation between SCP3 and VEGF-C or VEGF-D in various human lung cancer cell lines. Subsequently, we assessed SCP3, VEGF-A, VEGF-B, VEGF-C, and VEGF-D expression in archival tumor tissues from 89 NSCLC patients with lymph node (LN) metastasis by combined immunohistochemistry with quantitative digital image analysis.

Results

Positive correlations between SCP3 and VEGF-C expression (R 2  = 0.743) and VEGF-D expression (R 2  = 0.932) were detected in various human lung cancer cell lines. The high expression of SCP3, VEGF-A, VEGF-B, VEGF-C, and VEGF-D were detected in 24 (27.0%), 22 (24.7%), 27 (30.3%), 27 (30.3%), and 24 cases (27.0%), respectively. Notably, SCP3 positively correlated with VEGF-C and VEGF-D expression (for both, P < 0.001) and negatively correlated with VEGF-A and VEGF-B expression (P = 0.029 and P = 0.026, respectively). In multivariate analysis of patients with LN metastasis, SCP3 expression predicted worse overall survival (hazard ratio = 1.86, P = 0.008).

Conclusions

SCP3 is associated with lymphangiogenesis and provides insight into the SCP3-VEGF-C/VEGF-D axis based cancer therapy strategy.

Keywords

SCP3 Vascular endothelial growth factor Lymphangiogenesis Lymph node metastasis Non-small cell lung cancer

Background

Lung cancer is the leading cause of cancer-related deaths in the United States, accounting for 157,000 deaths annually [1]. Only 15% of lung cancer cases are diagnosed at an early stage, whereas 22% are diagnosed by the time the tumor has already spread to the lymph nodes. Median survival time is 84 months for lymph node (LN) negative patients, compared to 30 months for N1, 33 months for N2 single positive, and 11 months for N2 multi [2]. In addition, metastasis is common in lung cancer and is considered to be a critical factor in determining prognosis. Correctively, determining the extent of LN involvement is assessing the patients’ prognosis and choosing the optimal therapeutic strategy.

Angiogenesis and lymphangiogenesis play key roles in tumor growth and metastasis in non-small cell lung cancer (NSCLC). The balance between angiogenic and lymphangiogenic factors regulates tumor progression and metastasis [3]. Angiogenesis in NSCLC is, commonly associated with concomitant lymphangiogenesis. However, lymphangiogenesis is considered to be the key initial step in lymphatic and regional LN metastasis [4]. Although the significance of angiogenesis for tumor growth and metastasis has been well understood, the molecular mechanisms of lymphangiogenesis and lymphatic metastasis in tumor metastasis remain unclear [5]. The members of the vascular endothelial growth factor (VEGF) family are considered to be major mediators of both tumor angiogenesis and lymphangiogenesis [6]. Among the VEGF family members, VEGF-C and VEGF-D are known as key molecules that mediate the formation of tumor lymphatics as well as metastatic spread of tumor cells to lymph nodes via vascular endothelial growth factor-3 (VEGFR-3) [4, 5, 7]. The extent to which LN metastases promote the spreading of the tumor cells is no yet clear [8]. Thus, the prognostic significance of potential lymphangiogenic markers remains controversial [9].

Synaptonemal complex protein 3 (SCP3) is a DNA-binding protein and a structural component of the synaptonemal complex, which mediates the synapsis or homologous pairing of chromosomes during human spermatogenesis. Although SCP3 expression is highly restricted in the nucleus of meiotic germ cells, ectopic SCP3 expression is frequently observed in human cancers, such as acute lymphoblastic leukemia and cervical cancer [10, 11]. We previously demonstrated that SCP3 was significantly associated with cervical cancer progression and LN metastasis of cervical cancer [12], while SCP3 has been defined as a negative prognostic factor in the early stage of NSCLC by immunohistochemistry (IHC) and manual visual scoring [13]. This discrepancy may be explained by the subjectivity of assessing SCP3 positivity. Although visual scoring is the golden standard method for quantifying IHC staining, there are limitations such as quasi-continuous variable data, subjectivity by examiner, and less than optimal reproducibility [1416]. On the other hand, quantitative digital image analysis may overcome many of these limitations. Thus, we tried to reduce artifacts by using a quantitative digital image analysis program for IHC scoring in the present study. In an effort to understand the role SCP3 plays in NSCLC, we examined its potential relationship to LN metastasis by IHC and quantitative image analysis. Based on this pattern of expression, and in combination with investigation into the expression of VEGF-family members in NSCLC, we further investigated these relationships.

Methods

Cells

H146, H460, H1299, H1666, H2228, H358, and H3122 cell lines were obtained from American type culture collection (ATCC, Manassas, VA). All cells were maintained in RPMI-1640 supplemented with 10% FBS in the presence of 5% CO2 at 37 °C in a humidified incubator. H358/no insert, H358/SCP3, H1666/no insert and H1666/SCP3 cells were generated by retroviral transduction with pMSCV/empty (Clontech, Mountain View, CA) or pMSCV/SCP3 as previously described [11].

Synthetic small interfering RNAs constructs

Synthetic small interfering RNAs (siRNAs) specific for green fluorescent protein (GFP) or human SCP3 (hSCP3) were purchased from the Invitrogen (Invitrogen, Carlsbad, CA); GFP, 5′-GCAUCAAGGUGAACUUCAA-3′ (sense), 5′-UUGAAGUUCACCUUGAUGC-3′ (anti-sense); hSCP3, 5′-GGAGAAGAAUCAUGAUAAU-3′ (sense), 5′-AUUAUCAUGAUUCUUC-UCC-3′ (anti-sense). For in vitro delivery, tumor cells on a six-well vessel were transfected with 300 pmol of synthesized siRNAs using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions.

Western blot analysis

To determine the expressional levels of proteins, 50 μg of protein were separated on SDS-PAGE and transferred to nitrocellulose membrane. The membranes were blocked with 5% nonfat dry milk in TBST (50 mM Tris, pH 7.5, 150 mM NaCl, 0.05% Tween-20) for 1 h, washed, and subsequently incubated overnight at 4 °C in TBST with 5% BSA containing the following antibodies: mouse monoclonal anti-SCP3 (clone# 25/SCP3; 0.5 µg/ml; BD Bioscience, San Jose, CA), goat polyclonal anti-VEGF-C (cat.# AF752; 0.5 µg/ml; R&D Systems, Minneapolis, MN), goat polyclonal anti-VEGF-D (cat.# AF286; 0.5 µg/ml; R&D Systems) and mouse monoclonal anti-β-actin (clone# AC-74; 0.5 µg/ml; Sigma-Aldrich, St. Louis, MO). Specific molecules were detected with HRP-labeled anti-mouse or anti-rabbit secondary antibodies (Pierce, Rockford, IL) and enhanced with ECL kit (Elpis Biotech, Korea). Densitometry was performed using an image analyzer Fujifilm LAS-400 (Fuji, Tokyo, Japan) and Image J densitometry software (Version 1.6, National Institutes of Health, Bethesda, MD) was used for analysis.

Tissue samples

A total of 89 NSCLC cases with LN metastasis were prospectively selected from patients who were enrolled at Toyama University Hospital and National Hospital Organization Higashi-Ohmi General Medical Center. All patients underwent complete resections between 1988 and 2010, but did not receive neoadjuvant chemo or radio-therapy. Survival time and outcome data were available for all patients. Tumors were staged according to the International Union against cancer’s tumor-node-metastasis (TNM) classification. The histology was classified and graded according to 2004 World Health Organization guidelines [17]. The follow-up period ranged from 10 to 153 months.

Tissue microarray and immunohistochemistry

Tissue microarray (TMA) was constructed from archival formalin-fixed, paraffin-embedded tissue blocks. Three 1.0 mm diameter tissue cores were arrayed on a recipient paraffin block using a tissue arrayer (Pathology Devices, Westminster, MD). Briefly, a representative tumor area was carefully selected for each tumor from hematoxylin and eosin (H&E) stained section of a donor block. TMA blocks were cut into serial 5-µm-thick sections, and then sections were deparaffinized in xylene and were rehydrated through a graded alcohol series to distilled water. Immunohistochemistry for SCP3 was performed as previously described [13]. For VEGF-A, VEGF-B, VEGF-C and VEGF-D, endogenous peroxidase was blocked using a 3% solution of aqueous hydrogen peroxide. Immunohistochemical staining was performed with the following primary antibodies: mouse monoclonal anti-VEGF-A (clone# 16F1; diluted 1:100; Thermo scientific, Waltham, MA), mouse monoclonal anti-VEGF-B (clone# MM0008-7B43; diluted 1:100; Abcam, Cambridge, MA), goat polyclonal anti-VEGF-C (Cat.# AF752; diluted 1:100; R&D Systems), and goat polyclonal anti VEGF-D (cat.# AF286; diluted 1:100; R&D systems). Antigen retrieval for VEGF-C and VEGF-D was performed using a pressure chamber (Pascal; Dako, Carpinteria, CA) with pH 6 target retrieval solution (Dako). For VEGF-A and VEGF-B antibodies, the TMA slide was pretreated with pH 9 target retrieval solution (Dako). After antigen retrieval, slides were incubated with primary antibodies for 30 min (VEGF-A) or overnight (VEGF-B, VEGF-C and VEGF-D) at 4 °C. Signals were detected with LSAB detection system (Dako) for VEGF-C and VEGF-D, and with Envision+ detect system (Dako) for the other antibodies. The stain was visualized using DAB (Dako) and then was lightly counterstained with hematoxylin, dehydrated in ethanol, and cleared in xylene. Negative controls were processed by omitting the primary antibodies, and TMA included testis positive control tissues. The cut-off values of histoscore were identified considering the distribution and prognostic significance of the values (Additional file 1: Figure S1).

Digital image analysis

The immunohistochemical staining was assessed using computer-assisted image analysis software, as described previously [18]. In brief, immunohistochemically stained slides were scanned by the NanoZoomer 2.0 HT (Hamamatsu Photonics K.K., Japan) at ×20 objective magnification (0.5 μm resolution). Captured images were analyzed using Visiopharm Digital Image Analysis (DIA) software (for Windows 7, version 4.5.1.324; Visiopharm, Hørsholm, Denmark). First, transformation of an image from one form to another (image processing) is carried out to enhance relative image structures for subsequent image segmentation. After training the system by digitally “painting” examples of the nucleus in the image, tumor nuclei were defined during segmentation. The cytoplasm was further defined by outlining the defined nucleus. The pixels that contribute to positive staining were identified based on a DAB color deconvolution. The algorithm evaluated each pixel on the value of 0–255. We used the mean of the pixel intensity values as the quantity of protein expression. Cut-off values of histoscore were identified considering the distribution and prognostic significance of the values (Additional file 1: Figure S1).

Statistical analysis

Statistical analysis was performed using JMP Statistical Discovery Software, Version 7.0.1 (SAS Institute, Cary, NC). Chi square tests were used to evaluate the association between SCP3 and VEGFs. Survival analysis was performed for all cases. Kaplan–Meier survival analysis was used to determine the univariate relationship of SCP3 expression and overall survival, and survival curves were compared by using the log-rank test. Multivariate proportional Cox models with adjustments for antibody expression, age at diagnosis, gender, T factor, and cancer type were used. P values were considered significant when they were less than 0.05. Regression analyses were performed using the mean of the pixel intensity values of SCP3 and VEGFs. The response surfaces showed the correlation between SCP3, VEGFs and N factor (N1 or N2–N3).

Results

Relationship between SCP3 and VEGF-C or VEGF-D expression in human lung cancer cells

Given that SCP3 had been implicated in cervical cancer and metastasis to lymph nodes, we decided to examine its role in lung cancer. It has been known that VEGF-C and VEGF-D are associated with tumor lymphangiogenesis and metastasis [19, 20]. Thus, we measured the expression of SCP3, VEGF-C, and VEGF-D using human lung cancer cell lines. We observed a correlation between SCP3 and VEGF-C or VEGF-D in various human lung cancer cell lines (Fig. 1). Notably, linear regression analysis demonstrated that the level of SCP3 expression positively correlated with VEGF-C (R 2 = 0.555) or VEGF-D (R 2 = 0.867) in various human lung cancer cell lines (Fig. 1b). We further examined whether the relationship between SCP3 and VEGF-C or SCP3 and VEGF-D was conserved in human lung cancer cells. Consistently, we observed decreased levels of VEGF-C and VEGF-D when endogenous SCP3 high tumor cells (H1299) were treated with siRNA targeting to SCP3 (siSCP3) but not with non-specific control siRNA targeting GFP (siGFP). Conversely, increased VEGF-C and VEGF-D levels among H358 and H1666 cells expressing low levels of SCP3 were observed after over-expressing hSCP3 by a retroviral system (Fig. 1c, d).
Fig. 1

Correlation between SCP3 and VEGF-C or VEGF-D expressions in human lung cancer cells. a Western blot analysis to characterize the expression of SCP3, VEGF-C and VEGF-D in various human lung adenocarcinoma cells; H146, H460, H1299, H1666, H2228, H358, and H3122. b A plot graph demonstrating the linear relationship between expressing SCP3 (x-axis) and VEGF-C or VEGF-D (y-axis). Western blot analysis of SCP3 expression in lung cancer cell lines cells retrovirally transduced with a pMSCV vector encoding SCP3. c siGFP- or siScp3 transfected with H1299 d H358 and H1666 cells, retrovirally transduced with PMSCV vector encoding either no insert (H358/no insert, H1666/no insert) or Scp3 (H358/SCP3, H1666/SCP3), were incubated in 0.1% FBS-containing DMEM medium for 24 h

Expression of SCP3 and VEGFs in NSCLC

We performed immunohistochemistry on 89 formalin-fixed paraffin-embedded tissues from NSCLC patients with LN metastasis for investigated the expression of SCP3, VEGF-A, VEGF-B, VEGF-C, and VEGF-D. Forty-six (51.7%) patients were N1 and 43 (48.3%) patients were N2–3 (Additional file 2: Table S1). Expression of SCP3 and all examined VEGFs was primarily detected in cytoplasm (Fig. 2), and the rate of high expression ranged from 24.7 to 30.3% (Table 1). No correlations between clinicopathological factors and SCP3 or VEGFs expression was observed, except for the association between VEGF-D and tumor type (P = 0.02, Table 1).
Fig. 2

Representative immunohistochemical images of SCP3, VEGF-A, VEGF-B, VEGF-C and VEGF-D in formalin-fixed, paraffin-embedded non-small cell lung cancer (NSCLC) tissues. Scale bar = 100 μm

Table 1

Clinicopathological parameters of patients with SCP3, VEGF-A, VEGF-B, VEGF-C, and VEGF-D expression

Category

No. of case

Expression

SCP3

VEGF-A

VEGF-B

VEGF-C

VEGF-D

Low, n (%)

High, n (%)

P

Low, n (%)

High, n (%)

P

Low, n (%)

High, n (%)

P

Low, n (%)

High, n (%)

P

Low, n (%)

High, n (%)

P

Total

89

65 (73)

24 (27)

 

67 (75)

22 (25)

 

62 (70)

27 (30)

 

62 (70)

27 (30)

 

65 (73)

24 (27)

 

Gender

   

0.24

  

0.51

  

0.83

  

0.76

  

0.24

 Male

64

49 (76)

15 (24)

 

47 (73)

17 (27)

 

45 (70)

19 (30)

 

44 (69)

20 (31)

 

49 (77)

15 (23)

 

 Female

25

16 (64)

9 (36)

20 (80)

5 (20)

17 (68)

8 (32)

18 (72)

7 (28)

16 (64)

9 (36)

Age (year)

   

0.69

  

0.13

  

0.76

  

0.40

  

0.89

 <60

25

19 (76)

6 (24)

 

16 (64)

9 (36)

 

44 (69)

20 (31)

 

19 (76)

6 (24)

 

18 (72)

7 (28)

 

 ≥60

64

46 (72)

18 (28)

51 (80)

13 (20)

18 (72)

7 (28)

43 (67)

21 (33)

47 (73)

17 (27)

Smoking

   

0.31

  

0.30

  

0.77

  

0.14

  

0.58

 Never

19

20 (100)

0 (0)

 

11 (58)

6 (42)

 

11 (58)

8 (42)

 

17 (89)

2 (11)

 

16 (84)

3 (16)

 

 Ever

29

28 (97)

1 (3)

21 (72)

8 (28)

18 (62)

11 (38)

21 (72)

8 (28)

26 (90)

3 (10)

Stage

   

0.18

  

0.66

  

0.60

  

0.68

  

0.56

 II

40

32 (80)

8 (20)

 

31 (78)

9 (22)

 

29 (73)

11 (28)

 

27 (68)

13 (32)

 

28 (70)

12 (30)

 

 III–IV

49

33 (67)

16 (33)

46 (73)

13 (27)

33 (67)

16 (33)

35 (71)

14 (29)

37 (76)

12 (24)

T stage

   

0.49

  

0.64

  

0.32

  

0.78

  

0.22

 T1

15

12 (80)

3 (20)

 

12 (80)

3 (20)

 

12 (80)

3 (20)

 

10 (67)

5 (33)

 

9 (60)

6 (40)

 

 T2–4

74

53 (72)

21 (28)

55 (74)

19 (26)

50 (68)

24 (32)

52 (70)

22 (30)

56 (76)

18 (24)

Tumor type

   

0.18

  

0.95

  

0.33

  

0.16

  

0.02

 AD

53

36 (68)

17 (32)

 

40 (75)

13 (25)

 

39 (74)

14 (26)

 

34 (64)

19 (36)

 

34 (64)

19 (36)

 

 SCC

36

29 (81)

7 (19)

27 (75)

9 (25)

23 (64)

13 (36)

28 (78)

8 (22)

31 (86)

5 (14)

NSCLC non-small cell lung cancer, AD adenocarcinoma, SCC squamous cell carcinoma

Correlations between SCP3 and VEGF family member expression

To explore the association between SCP3 and lymphangiogenetic factors, we further examined correlation between SCP3 and VEGF family member expression using Pearson Chi square test (Table 2). SCP3 expression showed significant positive correlation with VEGF-C (odds ratio [OR] = 5.600, P < 0.001) and VEGF-D (OR = 7.700, P < 0.001), whereas SCP3 expression was negatively correlated with VEGF-A (OR = 0.205, P = 0.019) and VEGF-B (OR = 0.244, P = 0.019). Furthermore, SCP3 expression inversely correlated with increased VEGF-A and VEGF-B expression, and both VEGF-A and VEGF-B expressions levels also inversely correlated with LN metastasis status (Fig. 3).
Table 2

Association between SCP3 and VEGF-A, VEGF-B, VEGF-C or VEGF-D expression in NSCLC patients with LN metastasis

SCP3 expression

 

High no. (%)

Low no. (%)

Odds ratio (95% CI)

p value

VEGF-A

  

0.205 (0.044–0.955)

0.029

 High

2 (9)

20 (91)

  

 Low

22 (33)

45 (67)

  

VEGF-B

  

0.244 (0.066–0.905)

0.026

 High

3 (11)

24 (89)

  

 Low

21 (34)

41 (66)

  

VEGF-C

  

5.600 (2.032–15.435)

<0.001

 High

14 (52)

13 (48)

  

 Low

10 (16)

52 (84)

  

VEGF-D

  

7.700 (2.682–22.109)

<0.001

 High

14 (58)

10 (42)

  

 Low

10 (15)

55 (85)

  

NSCLC non-small cell lung cancer, VEGF vascular endothelial growth factor, LN lymph node, CI confidence interval

Fig. 3

Association between SCP3 and VEGFs in human non-small cell lung cancer (NSCLC). Correlation between SCP3, N factor (pN1 and pN2–3), and VEGF-A (a), VEGF-B (b), VEGF-C (c) or VEGF-D (d)

Prognostic implications of SCP3 expression in lung cancer

Analysis of patient survival was performed by Kaplan–Meier plots and log-rank analysis. Median survival time for patients with high SCP3 expression was significantly worse (median, 16 months) than that for patients with low expression (median, 66 months; p = 0.008; Fig. 4). No significant survival differences were observed for any tested VEGF family member. After adjustments for age, gender, cancer type, T factor and other antibodies, SCP3 remained significant (P = 0.008) and showed higher hazard ratio (HR) than T factor (HR; 1.86 with SCP3 and 1.80 with T factor) by a Cox proportional hazards regression model (Table 3).
Fig. 4

Kaplan–Meier survival curves for non-small cell lung cancer (NSCLC) patients with lymph node metastasis. a Patients with high SCP3 expression (median survival, 16 months) showed significantly worse survival than those with low SCP3 expression (median survival, 66 months). b No significance in survival differences was observed for patients with expression of different VEGFs

Table 3

Multivariate analysis of the association between prognostic variables and overall survival in NSCLC

Variables

Hazard ratio (95% CI)

p value

Age

0.76 (0.47–1.27)

0.280

Gender

0.54 (0.30–0.92)

0.030

T factor

1.80 (1.04–3.43)

0.040

Cancer type

0.98 (0.66–1.50)

0.800

SCP3 expression

1.86 (1.17–2.91)

0.008

VEGF-A expression

1.05 (0.63–1.62)

0.840

VEGF-B expression

1.05 (0.67–1.50)

0.800

VEGF-C expression

1.20 (0.83–1.73)

0.330

VEGF-D expression

0.95 (0.58–1.51)

0.820

NSCLC non-small cell lung cancer, CI confidence interval, VEGF vascular endothelial growth

Discussion

Lung cancer has poor prognosis because most patients present with advanced or metastatic disease at the time of diagnosis. The metastatic spread of malignant cells occurs via lymphatic or vascular spread and is considered to be one of the most critical prognostic factors in NSCLC. Indeed, the detection of cancer cells in lymphatic vessels and LNs is a key criterion in the staging of NSCLC and has been used to develop therapeutic strategies. Currently, the axis of VEGF-C/VEGF-D/VEGFR-3 thought to be a major mediator of tumor lymphangiogenesis. VEGF-C and VEGF-D overexpression in the mouse tumor model can induce lymphangiogenesis and promote lymphatic metastasis of tumor cells [21], whereas suppression of VEGFR-3 signaling inhibits LN metastasis in gastric cancer [22]. Although several studies have shown that the VEGF-C/VEGF-D/VEGFR-3 axis promotes lymphangiogenesis in cancer, the molecular mechanism of lymphangiogenesis is not yet fully understood.

Prior studies have shown VEGF-C and VEGF-D overexpression in tumor cells can led to the formation new lymphatic vessels and the promotion of LN and distant-organ metastases [19, 20, 2327]. Overexpression of VEGF-C can certainly enhance tumor lymphangiogenesis as well as nodal and distant-organ metastasis [25, 26], whereas knockdown of VEGF-C can reduce LN and lung metastases [28, 29]. Wen et al. have also demonstrated that up-regulated VEGF-D expression can promote tumor-associated lymph angiogenesis and lymphatic metastasis using murine LN metastasis models [30, 31]. In prior study, we have shown that SCP3 overexpression was associated with T factor in the early stage of NSCLC patients [13]. Recent study have showed that SCP3 overexpression is associated with poor prognosis of patients with cervical cancer [12]. However, the association of SCP3 with VEGF-C, VEGF-D and lymphangiogenesis is unknown. In the present study, we demonstrate that SCP3 overexpression correlated with VEGF-C and VEGF-D expression in NSCLC patients with LN metastasis. We evaluated 68 patients without lymph node metastasis from the same patient population, and failed to find a relationship of SCP3 expression with VEGF-C or VEGF-D, nor was there an association with survival for any of the factors examined (data not shown). These data suggest that SCP3 is closely associated with some process in lymphangiogenesis in NSCLC. To the best of our knowledge, this is the first study to identify a positive correlation between SCP3 and VEGF-C or VEGF-D expression levels in NSCLC patients with lymph node metastasis.

We previously demonstrated that SCP3 was linked with LN metastasis of cervical cancer [12], whereas SCP3 was associated with poor outcome in early stage of NSCLC by immunohistochemistry (IHC) and manual visual scoring [13]. Although immunohistochemistry is providing excellent localization on the examined tissue, lacks quantification without sophisticated instrumentation and normalization tool in chromogenic applications. In previous study, we evaluated SCP3 expressional level by traditional visual scoring which is fraught with data quality problems. IHC data resulted from traditional manual scoring has good to excellent intra- and inter-observer reproducibility [3234]. However, estimation of negative and positive percentages of areas stained has only poor to good reproducibility [16]. Notably, prior studies demonstrated that continuous IHC score data resulted from digital image analysis may allow identification of IHC cut-off points of prognostic relevance that are either undetected [35] or are less statistically significant [36, 37] by manual visual scoring. In the present study, we observed higher SCP3 positivity compared to the previous study [13]. This discrepancy in the findings may be resulted from employed IHC scoring method and lack of well-defined SCP3 cut-off values for positive and negative results. Although image analysis allows reproducible data with high throughput mode in the hands of a well-trained pathologist, a well-defined algorithm and cut-off values for SCP3 stain remains to be developed for the clinical utility.

The prognostic value of VEGF-A, VEGF-B, VEGF-C and VEGF-D is still controversial. A number of studies has shown a direct correlation between expression of VEGF-C or VEGF-D in tumor cells and the metastatic tumor spread of many human cancers [3240]. Chen et al. reported that VEGF-C may be a predictor of early post-operative recurrence in patients with N2 NSCLC [35], and Maekawa et al. showed that VEGF-D expression indicated poor prognosis in lung cancer patients with T1 adenocarcinoma [39]. In contrast, Liao et al. showed VEGF expression was not associated with survival in NSCLC. Likewise, Tomita et al. reported that there is no relationship between VEGF expression and survival rate in patients with N2 NSCLC [41]. In this study, we observed that although VEGFs do not show prognostic significance, SCP3 expression is a prognostic factor. These discrepancies may be explained by the lack of standardized methodology, different standards of interpretation, or differences in patient population among the various studies.

To better understand the mechanism by which SCP3 promotes lymphangiogenesis, we examined SCP3, VEGF-C and VEGF-D expression in human lung cancer cell lines using western blotting. Overexpressed SCP3 positively correlated with VEGF-C and VEGF-D expression (Fig. 1b). Inhibition of SCP3 expression by SCP3 siRNA gene knockdown resulted in significant down-regulation of VEGF-C and VEGF-D expression. These results suggest that SCP3 may promote lymphangiogenesis by up-regulating VEGF-C and VEGF-D expression in tumor cells through an unknown signaling pathway. Among the known signaling pathways, the AKT pathway is a major candidate because it plays a pivotal role in transformation by inducing cell survival, proliferation, invasion, migration and angiogenesis [42, 43]. In prior study, we demonstrated that phospho-AKT levels were increased in SCP3-expressing cervical cell lines [11] and that SCP3 mediates an oncogenic phenotype of cervical cancer cells through an AKT-dependent pathway [12]. Further study is needed to demonstrate the details of SCP3’s involvement in lymphangiogenesis and whether there is any link between the up-regulation of lymphangiogenetic factors (VEGF-C and VEGF-D) and the AKT pathway.

Conclusions

In conclusion, SCP3 is significantly associated with VEGF-C and VEGF-D expression and can be used to indicate poor prognosis in NSCLC with LN metastasis. It seems likely that SCP3 expression can influence lymphangiogenesis by VEGF-C and VEGF-D upregulation separately from angiogenesis. Thus, SCP3 may be a potential therapeutic target, considering its possibly pivotal role in lymphangiogenesis. Further study of SCP3’s molecular mechanism may lead to the development of a novel therapeutic target for NSCLC.

Notes

Abbreviations

SCP3: 

synaptonemal complex protein 3

NSCLC: 

non-small cell lung cancer

LN: 

lymph node

VEGF: 

vascular endothelial growth factor

TNM: 

tumor-node-metastasis

siRNA: 

small interfering RNA

GFP: 

green fluorescent protein: TMA: tissue microarray

H&E: 

hematoxylin and eosin

OR: 

odds ratio

CI: 

confidence interval

Declarations

Authors’ contributions

HK, J-YCHC, JF and SMH conceived of the study and devised the experimental design. HK, J-YC, KHN, Y-HL, and CHC performed experiments. HK, J-YC, TWK, SHL, S-HE, HC, SI, JH, JF and SMH performed data analysis for experiments or clinical records. HK, J-YC and TWK drafted the final version of the manuscript and figure legends. JF and SMH revised the figures, added critical content to the discussion and were responsible in revising all portions of the submitted portion of the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We thank Kris Ylaya for technical assistances.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

Data is available in the Additional files.

Ethics approval and consent to participate

This study was approved by the ethics committee at Toyama University Hospital (Toyama, Japan) and National Hospital Organization Higashi-Ohmi General Medical Center (Shiga, Japan), and informed consent was obtained from each patient. This study was additionally approved by the Office of Human Subjects Research at the National Institutes of Health.

Funding

This research was supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health
(2)
Department of Biomedical Sciences, Graduate School of Medicine, Korea University
(3)
Department of Biochemistry & Molecular Biology, Korea University College of Medicine
(4)
Department of Statistics, Korea University
(5)
Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine
(6)
Department of Thoracic Surgery, National Hospital Organization Higashi-Ohmi General Medical Center
(7)
Department of Thoracic Surgery, Shiga University of Medical Science
(8)
Department of Pathology, Nagasaki University Graduate School of Biomedical Sciences

References

  1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.View ArticlePubMedGoogle Scholar
  2. Marra A, Richardsen G, Wagner W, Muller-Tidow C, Koch OM, Hillejan L. Prognostic factors of resected node-positive lung cancer: location, extent of nodal metastases, and multimodal treatment. Thorac Surg Sci. 2011;8:1–13.Google Scholar
  3. Stacker SA, Williams SP, Karnezis T, Shayan R, Fox SB, Achen MG. Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nat Rev Cancer. 2014;14:159–72.View ArticlePubMedGoogle Scholar
  4. El-Chemaly S, Levine SJ, Moss J. Lymphatics in lung disease. Ann NY Acad Sci. 2008;1131:195–202.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer. 2002;2:573–83.View ArticlePubMedGoogle Scholar
  6. Otrock ZK, Makarem JA, Shamseddine AI. Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells Mol Dis. 2007;38:258–68.View ArticlePubMedGoogle Scholar
  7. Renyi-Vamos F, Tovari J, Fillinger J, Timar J, Paku S, Kenessey I, Ostoros G, Agocs L, Soltesz I, Dome B. Lymphangiogenesis correlates with lymph node metastasis, prognosis, and angiogenic phenotype in human non-small cell lung cancer. Clin Cancer Res. 2005;11:7344–53.View ArticlePubMedGoogle Scholar
  8. Sleeman JP, Nazarenko I, Thiele W. Do all roads lead to Rome? Routes to metastasis development. Int J Cancer. 2011;128:2511–26.View ArticlePubMedGoogle Scholar
  9. Anagnostou VK, Tiniakos DG, Fotinou M, Achimastos A, Syrigos KN. Multiplexed analysis of angiogenesis and lymphangiogenesis factors predicts outcome for non-small cell lung cancer patients. Virchows Arch. 2011;458:331–40.View ArticlePubMedGoogle Scholar
  10. Niemeyer P, Tureci O, Eberle T, Graf N, Pfreundschuh M, Sahin U. Expression of serologically identified tumor antigens in acute leukemias. Leuk Res. 2003;27:655–60.View ArticlePubMedGoogle Scholar
  11. Kang TH, Noh KH, Kim JH, Bae HC, Lin KY, Monie A, Pai SI, Hung CF, Wu TC, Kim TW. Ectopic expression of X-linked lymphocyte-regulated protein pM1 renders tumor cells resistant to antitumor immunity. Cancer Res. 2010;70:3062–70.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Cho H, Noh KH, Chung JY, Takikita M, Chung EJ, Kim BW, Hewitt SM, Kim TW, Kim JH. Synaptonemal complex protein 3 is a prognostic marker in cervical cancer. PLoS ONE. 2014;9:e98712.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Chung JY, Kitano H, Takikita M, Cho H, Noh KH, Kim TW, Ylaya K, Hanaoka J, Fukuoka J, Hewitt SM. Synaptonemal complex protein 3 as a novel prognostic marker in early stage non-small cell lung cancer. Hum Pathol. 2013;44:472–9.View ArticlePubMedGoogle Scholar
  14. Rimm DL. What brown cannot do for you. Nat Biotechnol. 2006;24:914–6.View ArticlePubMedGoogle Scholar
  15. Weaver DL, Krag DN, Manna EA, Ashikaga T, Harlow SP, Bauer KD. Comparison of pathologist-detected and automated computer-assisted image analysis detected sentinel lymph node micrometastases in breast cancer. Mod Pathol. 2003;16:1159–63.View ArticlePubMedGoogle Scholar
  16. Jaraj SJ, Camparo P, Boyle H, Germain F, Nilsson B, Petersson F, Egevad L. Intra- and interobserver reproducibility of interpretation of immunohistochemical stains of prostate cancer. Virchows Arch. 2009;455:375–81.View ArticlePubMedGoogle Scholar
  17. Fukuoka J, Fujii T, Shih JH, Dracheva T, Meerzaman D, Player A, Hong K, Settnek S, Gupta A, Buetow K, et al. Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer. Clin Cancer Res. 2004;10:4314–24.View ArticlePubMedGoogle Scholar
  18. Choi CH, Chung JY, Kim JH, Kim BG, Hewitt SM. Expression of fibroblast growth factor receptor family members is associated with prognosis in early stage cervical cancer patients. J Transl Med. 2016;14:124.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K, Detmar M. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med. 2001;7:192–8.View ArticlePubMedGoogle Scholar
  20. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, Jackson DG, Nishikawa S, Kubo H, Achen MG. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med. 2001;7:186–91.View ArticlePubMedGoogle Scholar
  21. Veikkola T, Jussila L, Makinen T, Karpanen T, Jeltsch M, Petrova TV, Kubo H, Thurston G, McDonald DM, Achen MG, et al. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J. 2001;20:1223–31.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Shimizu K, Kubo H, Yamaguchi K, Kawashima K, Ueda Y, Matsuo K, Awane M, Shimahara Y, Takabayashi A, Yamaoka Y, et al. Suppression of VEGFR-3 signaling inhibits lymph node metastasis in gastric cancer. Cancer Sci. 2004;95:328–33.View ArticlePubMedGoogle Scholar
  23. Yokoyama Y, Charnock-Jones DS, Licence D, Yanaihara A, Hastings JM, Holland CM, Emoto M, Sakamoto A, Sakamoto T, Maruyama H, et al. Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma. Clin Cancer Res. 2003;9:1361–9.PubMedGoogle Scholar
  24. Lin J, Lalani AS, Harding TC, Gonzalez M, Wu WW, Luan B, Tu GH, Koprivnikar K, VanRoey MJ, He Y, et al. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res. 2005;65:6901–9.View ArticlePubMedGoogle Scholar
  25. Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R, Banerji S, Huarte J, Montesano R, Jackson DG, et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J. 2001;20:672–82.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Yla-Herttuala S, Jaattela M, Alitalo K. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res. 2001;61:1786–90.PubMedGoogle Scholar
  27. Yanai Y, Furuhata T, Kimura Y, Yamaguchi K, Yasoshima T, Mitaka T, Mochizuki Y, Hirata K. Vascular endothelial growth factor C promotes human gastric carcinoma lymph node metastasis in mice. J Exp Clin Cancer Res. 2001;20:419–28.PubMedGoogle Scholar
  28. Shibata MA, Morimoto J, Shibata E, Otsuki Y. Combination therapy with short interfering RNA vectors against VEGF-C and VEGF-A suppresses lymph node and lung metastasis in a mouse immunocompetent mammary cancer model. Cancer Gene Ther. 2008;15:776–86.View ArticlePubMedGoogle Scholar
  29. Chen Z, Varney ML, Backora MW, Cowan K, Solheim JC, Talmadge JE, Singh RK. Down-regulation of vascular endothelial cell growth factor-C expression using small interfering RNA vectors in mammary tumors inhibits tumor lymphangiogenesis and spontaneous metastasis and enhances survival. Cancer Res. 2005;65:9004–11.View ArticlePubMedGoogle Scholar
  30. Wen J, Fu AF, Chen LJ, Xie XJ, Yang GL, Chen XC, Wang YS, Li J, Chen P, Tang MH, et al. Liposomal honokiol inhibits VEGF-D-induced lymphangiogenesis and metastasis in xenograft tumor model. Int J Cancer. 2009;124:2709–18.View ArticlePubMedGoogle Scholar
  31. Hu J, Ye H, Fu A, Chen X, Wang Y, Ye X, Xiao W, Duan X, Wei Y, Chen L. Deguelin—an inhibitor to tumor lymphangiogenesis and lymphatic metastasis by downregulation of vascular endothelial cell growth factor-D in lung tumor model. Int J Cancer. 2010;127:2455–66.View ArticlePubMedGoogle Scholar
  32. Arinaga M, Noguchi T, Takeno S, Chujo M, Miura T, Uchida Y. Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma. Cancer. 2003;97:457–64.View ArticlePubMedGoogle Scholar
  33. Bo C, Xiaopeng D, Chuanliang P, Xiaogang Z. Expression of vascular endothelial growth factors C and D correlates with lymphangiogenesis and lymph node metastasis in lung adenocarcinoma. Thorac Cardiovasc Surg. 2009;57:291–4.View ArticlePubMedGoogle Scholar
  34. Bogos K, Renyi-Vamos F, Dobos J, Kenessey I, Tovari J, Timar J, Strausz J, Ostoros G, Klepetko W, Ankersmit HJ, et al. High VEGFR-3-positive circulating lymphatic/vascular endothelial progenitor cell level is associated with poor prognosis in human small cell lung cancer. Clin Cancer Res. 2009;15:1741–6.View ArticlePubMedGoogle Scholar
  35. Chen G, Liu XY, Wang Z, Liu FY. Vascular endothelial growth factor C: the predicator of early recurrence in patients with N2 non-small-cell lung cancer. Eur J Cardiothorac Surg. 2010;37:546–51.View ArticlePubMedGoogle Scholar
  36. Feng Y, Wang W, Hu J, Ma J, Zhang Y, Zhang J. Expression of VEGF-C and VEGF-D as significant markers for assessment of lymphangiogenesis and lymph node metastasis in non-small cell lung cancer. Anat Rec (Hoboken). 2010;293:802–12.View ArticleGoogle Scholar
  37. Gou HF, Chen XC, Zhu J, Jiang M, Yang Y, Cao D, Hou M. Expressions of COX-2 and VEGF-C in gastric cancer: correlations with lymphangiogenesis and prognostic implications. J Exp Clin Cancer Res. 2011;30:14.View ArticlePubMedPubMed CentralGoogle Scholar
  38. Guo X, Chen Y, Xu Z, Qian Y, Yu X. Prognostic significance of VEGF-C expression in correlation with COX-2, lymphatic microvessel density, and clinicopathologic characteristics in human non-small cell lung cancer. Acta Biochim Biophys Sin (Shanghai). 2009;41:217–22.View ArticleGoogle Scholar
  39. Maekawa S, Iwasaki A, Shirakusa T, Enatsu S, Kawakami T, Kuroki M. Correlation between lymph node metastasis and the expression of VEGF-C, VEGF-D and VEGFR-3 in T1 lung adenocarcinoma. Anticancer Res. 2007;27:3735–41.PubMedGoogle Scholar
  40. Saintigny P, Kambouchner M, Ly M, Gomes N, Sainte-Catherine O, Vassy R, Czernichow S, Letoumelin P, Breau JL, Bernaudin JF, et al. Vascular endothelial growth factor-C and its receptor VEGFR-3 in non-small-cell lung cancer: concurrent expression in cancer cells from primary tumour and metastatic lymph node. Lung Cancer. 2007;58:205–13.View ArticlePubMedGoogle Scholar
  41. Tomita M, Matsuzaki Y, Shimizu T, Hara M, Ayabe T, Onitsuka T. Vascular endothelial growth factor expression in pN2 non-small cell lung cancer: lack of prognostic value. Respirology. 2005;10:31–5.View ArticlePubMedGoogle Scholar
  42. Kim D, Dan HC, Park S, Yang L, Liu Q, Kaneko S, Ning J, He L, Yang H, Sun M, et al. AKT/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci. 2005;10:975–87.View ArticlePubMedGoogle Scholar
  43. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med. 2005;9:59–71.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s) 2017

Advertisement